Icarus Consultants to attend ASCO 2013 in Chicago

The 2013 annual meeting of the American Society of Clinical Oncology (ASCO) is fast approaching, and for many in cancer drug development, it is one of the landmarks of the year.

Chicago Skyline during ASCO 2012

This year, there’s a lot of interesting data on PD-1 and cancer immunotherapy, something we picked up on before the annual meeting last year.  Sally Church, PhD is in the process of finalizing her pre-ASCO video and it will be available soon.

For a meeting that is typically orientated around solid tumors, there is a lot of data at the meeting on Chronic Lymphocytic Leukemia (CLL).

The CLL landscape is set to change, with new treatment options on the horizon. Ibrutinib received FDA Breakthrough designation earlier this year in three different indications, and we will be writing more about this market in a forthcoming Pharma Strategy Report.

For those clients and potential clients interested in learning more about our capabilities or discussing our services, we will be in Chicago for ASCO – please do contact us if you would like to meet up.

, , , , , , , , , , , , , ,

error: Content is protected !!